Evolocumab is a new injectable drug that can further lower cholesterol levels in people taking statin drugs by inhibiting PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the bloodstream. It works by binding to PCSK9 as a human monoclonal antibody, preventing PCSK9 from binding to LDL receptors on the liver surface and allowing more LDL receptors to remove LDL-C from the blood. Evolocumab shows promise for treating people with genetic high cholesterol or those unable to take high statin doses, but it is expected to be an expensive drug if approved by the FDA. Further studies are underway to evaluate its long-term safety and outcomes.